Acadia Pharma (ACAD) Misses Q4 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. XYZ
9. FISV
10. CVS

Go back to Acadia Pharma (ACAD) Misses Q4 EPS by 1c

Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operating Overview

February 27, 2024 4:05 PM EST

- 2023 total net product sales of $726.4 million, reflecting 40% revenue growth.

- Fourth quarter DAYBUE (trofinetide) net product sales of $87.1 million and full year 2023 net product sales of $177.2 million.

- Fourth quarter NUPLAZID® (pimavanserin) net product sales of $143.9 million and full year 2023 net product sales of $549.2 million.

SAN DIEGO--(BUSINESS WIRE)-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the fourth quarter and full year ended December 31, 2023.

2023 was a transformational year for Acadia that positioned us for... More